MY ACCOUNT | NEWSLETTER |

Vetoquinol unveils new Flexadin products, launch of Simplera Otic Solution for dogs


Vetoquinol U.S.A. recently unveiled five new joint support products and the launch of Simplera Otic Solution for Dogs. 

Simplera Otic Solution It is the most affordable, single-dose treatment for canine otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius), according to a news release. The medication is FDA-approved as the first and only bioequivalent generic to Claro® (florfenicol, terbinafine, mometasone furoate) Otic Solution. 

Simplera Otic Solution

Ear infections are among the most common reasons pet owners seek veterinary care for their dogs, said Dr. Eric M. Alsup, DVM and general manager at Vetoquinol U.S.A. 

“Simplera is a leading-edge solution at an economical price, and it doesn’t rely on at-home treatment by clients,” he said. “This gives veterinarians the flexibility to treat effectively and affordably — while maximizing practice profitability and removing client compliance from the treatment equation.”

Simplera is effective for up to 30 days, giving pets lasting relief in just one dose using a combination of three active substances:

• Florfenicol, an antibacterial

• Terbinafine, an antifungal

• Mometasone furoate, a steroidal anti-inflammatory

Simplera was developed so that each antibacterial and antifungal works according to the indication. Each component was found to be compatible — and additive — in a study.

Simplera is made in North America, and Vetoquinol offers a 100% satisfaction guarantee available with its other quality generic medications like Vetprofen® (carprofen) and Imoxi™ (imidacloprid .+ moxidectin) Topical Solution.

New joint support products

The new Flexadin products are available as of Oct. 1 and include: 

• Flexadin Young Dog, a supplement for dogs from six months to two years old containing glucosamine. It is designed for active, younger animals and breeds prone to joint issues with eight ingredients to support joint health. 

• Flexadin Young Dog Mini, formulated for small-breed dogs from six months to two years old with glucosamine, creatine, Perna canaliculus (green-lipped mussel) and omega-3 fatty acids to help support joint health. 

• Flexadin Advanced for Cats has a cat-friendly shape and contains UC•II® for advanced joint support that can help slow cartilage loss. 

• Flexadin Adult Dog & Cat, formulated for pets more than two years old with advanced joint support containing UC-II®, which is clinically proven to be more effective than glucosamine and chondroitin.

• Flexadin Advanced Extra Strength with UC-II® offers once-a-day joint support for dogs and cats that is only available from a veterinarian. 

“As an industry, we’ve learned so much in the past 30 years,” said Vetoquinol’s Alsup. “Now, we know that glucosamine and chondroitin are ingredients that help maintain joint mobility in young dogs while older dogs may need advanced support under the care of a veterinarian. The full line of Flexadin products makes it easy to find a supplement that matches the needs of your pet.” 

Flexadin Advanced with UC-II® and Flexadin Plus will continue to be available to pet owners. Flexadin products can be purchased at veterinary clinics, authorized retailers, and https://store.myhappypets.com/joint-support/.  

About Vetoquinol USA 

Headquartered in Fort Worth, Texas, Vetoquinol U.S.A. is owned by Vetoquinol S.A., an independent, family-owned French pharmaceutical company founded in 1933. Dedicated exclusively to animal health, Vetoquinol U.S.A. is focused on the development, production, and marketing of FDA, EPA, NASC and AAFCO-regulated pharmaceutical, nutritional, and dermatological products for small and large animals. 

For more information, visit vetoquinolusa.com

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

World Veterinary Dermatology Day

Like0
Dislike0

Artificial insemination market to grow to $3B by 2028

Like0
Dislike0

February is National Pet Dental Health Month

Like0
Dislike0

Falling markets? Don't panic, it's not the first time

Like0
Dislike0

Treatment of canine chronic cutaneous lupus erythematosus with oclacitinib

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2023 - All Rights Reserved
ISSN 2768-198X

Top